The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

NCT ID: NCT02920554

Last Updated: 2024-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The extent of hepatic resection for gallbladder cancer can be done from a wedge resection to 4b/5 bisegmentectomy. This study aims to compare the recurrence rates and survival rates between wedge resection group and bisegmentectomy group. Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy were enrolled. All patients are randomly assigned to wedge resection or bisegmentectomy group. Number of patients in each group is 44. Primary endpoint is recurrence-free-survival rates and overall survival rates.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The extent of hepatic resection for gallbladder cancer has a wide range. A partial hepatectomy involving the gallbladder fossa is a critical part of the resection but can range from a wedge resection to an anatomic resection of segments 4b and 5 to an extended right hepatectomy. This study enrolls Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy. Eighty eight patients are randomized to wedge resection group or bisegmentectomy group. Except the extent of hepatic resection, all the procedures including hepatoduodenal,common hepatic, posterior pancreatic lymph node dissection are same.

Primary endpoint is recurrence-free-survival rates and overall survival rates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gallbladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

wedge resection

The extent of hepatic resection is wedge resection of gallbladder fossa

Group Type ACTIVE_COMPARATOR

wedge resection

Intervention Type PROCEDURE

The extent of hepatic resection is wedge resection of liver including gallbladder fossa

bisegmentectomy

The extent of hepatic resection is 4b/5 bisegmentectomy

Group Type ACTIVE_COMPARATOR

bisegmentectomy

Intervention Type PROCEDURE

The extent of hepatic resection is 4b/5 bisegmentectomy of liver

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

wedge resection

The extent of hepatic resection is wedge resection of liver including gallbladder fossa

Intervention Type PROCEDURE

bisegmentectomy

The extent of hepatic resection is 4b/5 bisegmentectomy of liver

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with T2 or T3 gallbladder cancer on preoperative CT exam
* Patients who are pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy

Exclusion Criteria

* Peritoneal seeding or distant metastasis
* Impossible to resect the cancer radically
* Pathologically diagnosed to other malignancy such as adenosquamous carcinoma, sarcoma, etc.
* R1 or R2 resection were pathologically diagnosed.
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saint Vincent's Hospital, Korea

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

YOU DONG DO

Associated Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dong Do You, MD, PhD

Role: STUDY_DIRECTOR

the Catholic Universityof Korea St. Vincent's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the Catholic University of Korea St. Vincent's Hospital

Suwon, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dong Do You, MD, PhD

Role: CONTACT

82-31-249-8303

Kwang Yeol Paik, MD, PhD

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XC14EIMI0009V

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.